Josh Holyfield argues that appetite suppression isn't the most important effect of retatrutide for anyone trying to change body composition. These are his views, not trial findings.
Recap by typeshit. Post by @josh.holyfield on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Edinburgh researchers say no more than half the drop in heart disease traced back to known risk factors, and suggest treating semaglutide as a heart drug too.
Eligible beneficiaries can get some GLP-1 drugs cheaper, but BMI and medical conditions decide who qualifies, and it runs apart from Part D.
Loading…